Cargando…
Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
Cytoreductive nephrectomy has been an integral part of management in metastatic renal cell carcinoma for patients with good performance status, based on the benefit shown by prospective trials in the interferon era and retrospective trials in the targeted therapies era. Clinical Trial to Assess the...
Autores principales: | Renner, Alex, Samtani, Suraj, Marín, Arnaldo, Burotto, Mauricio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403966/ https://www.ncbi.nlm.nih.gov/pubmed/30881867 http://dx.doi.org/10.15586/jkcvhl.2019.114 |
Ejemplares similares
-
The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
por: Umbreit, Eric C., et al.
Publicado: (2021) -
The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023) -
Cytoreductive Nephrectomy: Still Necessary in 2021
por: Méjean, Arnaud, et al.
Publicado: (2022) -
Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007) -
Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature
por: Salinas, Carlos, et al.
Publicado: (2020)